ArticleJACC. Advances2026
Female Sex Is Not a Uniform Risk Factor in Atrial Fibrillation.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFemale sex is a part of the stroke risk stratification in atrial fibrillation (AF), although emerging evidence suggests it may function as a risk modifier rather than an independent risk factor.
objectivesThis study aimed to determine whether female sex is a risk factor or risk modifier for stroke in patients with AF.
methodsUsing TriNetX, nonvalvular AF patients were identified and stratified by sex and age (<65, 65-74, and ≥75 years). Female and male patients were propensity matched for comorbidities and anticoagulation. Analyses were conducted comparing male and female patients with no CHA
resultsIn patients without additional CHA
conclusionsFemale sex acts as a modest risk modifier for thromboembolic stroke. Increased risk is primarily observed in patients with greater comorbidity burden or advanced age (≥75 years).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.